An Open-label, Phase II, Randomized, Pilot Study to Assess the Effect in Term of Erythroid Improvement of Deferasirox Combined With Erythropoietin Compared to Erythropoietin Alone in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.

Trial Profile

An Open-label, Phase II, Randomized, Pilot Study to Assess the Effect in Term of Erythroid Improvement of Deferasirox Combined With Erythropoietin Compared to Erythropoietin Alone in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Deferasirox (Primary) ; Erythropoietin
  • Indications Myelodysplastic syndromes
  • Focus Pharmacodynamics
  • Acronyms Kallisto
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 20 Feb 2018 Status changed from discontinued to completed.
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 Status changed from recruiting to discontinued because of enrollment issues, as per results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top